Clinical Trial Update: UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating UCN-01 in combination with fludarabine for recurrent or refractory leukemia or lymphoma; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Fludarabine (Fludarabine)
• UCN-01 (7-hydroxystaurosporine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED